Our Partners
Featured Research Study
The study is a Phase III, Placebo-controlled, Randomized, Observer-blinded, Multi-national, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) adjuvanted with AS03 in Adults Aged 18 Years and Older.
News and Updates
Register for the event: Healthcare Responding to Violence and Abuse in Brazil, Nepal, Sri Lanka and Occupied Palestinian Territories
Join us to discuss the findings of HERA (Healthcare Responding to Violence and Abuse), which over the last five years has been …
Dhulikhel Hospital and NRNA South Korea to Launch Telemedicine Health Consultation Services for Nepali Citizens in South Korea
In a significant move to support Nepali citizens residing in South Korea, Dhulikhel Hospital and the Non-Resident Nepali Association (NRNA) South Korea are set to launch a joint telemedicine health consultation service.
Healthcare Responding to Violence and Abuse (HERA) Dissemination
Healthcare Responding to Violence and Abuse (HERA) is a This is collaborative research between Dhulikhel Hospital, Kathmandu University Hospital, University at Bristol …